Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

ConditionOsteoarthritis of the Knees

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age19-75

SponsorAddpharma Inc.

About this trial

The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signed informed consent

Patients with osteoarthritis of the Knee

Other inclusions applied

Disqualifiers

Patients with secondary osteoarthritis of the knee

Other exclusions applied

Trial design

Design model

Parallel

Treatments tested in this trial

AD-211-L
Drug
Per oral, 1 tablet twice daily during the treatment period.
AD-211-M
Drug
Per oral, 1 tablet twice daily during the treatment period.
AD-211-H
Drug
Per oral, 1 tablet twice daily during the treatment period.
AD-2113
Drug
Per oral, 1 tablet twice daily during the treatment period.
Placebo to AD-211-L/M
Drug
Per oral, 1 tablet twice daily during the treatment period.
Placebo to AD-211-H
Drug
Per oral, 1 tablet twice daily during the treatment period.
Placebo to AD-2113
Drug
Per oral, 1 tablet twice daily during the treatment period.

Treatment groups

200 Participants

are divided into 4 treatment groups

Group A: AD-211-L GroupExperimental treatment 3 interventions

Group B: AD-211-M GroupExperimental treatment 3 interventions

Group C: AD-211-H GroupExperimental treatment 4 interventions

Group D: AD-2113 GroupActive comparator 3 interventions

Trial outcomes

Primary outcomes

Change from baseline in 100 mm Pain VAS score during activity over the past 24 hours in the target knee

Time frame

Baseline to Week13

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Addpharma Inc.

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: